Some aspects of radiation protection in radionuclide therapy departments
https://doi.org/10.21514/1998-426X-2021-14-1-75-85
Abstract
The paper presents the data that allow calculate the attenuation factors in lead, tungsten and concrete of various thicknesses or the thickness of shielding made of these materials for a given attenuation factor for the spectra of gamma radiation of 131I and 177Lu radionuclides. Using these data the effectiveness of the protection of supporting equipment (portable containers, shielded syringes, etc.) and the possible doses of external radiation of medical personnel in the radionuclide therapy department were calculated. It is shown that there are short-term operations in the production process when a radiation source (container with a capsule with activity, syringe with activity), being near the body of a medical worker, creates a significant dose rate. For this reason the annual individual dose of external exposure of a medical worker can approach or exceed 1/3 of the dose limit. Calculation of the attenuation of 131I gamma radiation by stationary shield showed that the thickness of walls and floors made of concrete 200 – 400 mm will ensure that the permissible values of the dose rates of gamma radiation in the air do not exceed at annual turnover of activity in the radionuclide therapy department of ~ 3.3 · 1012 Bq.
About the Authors
V. Yu. Golikov
Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being
Russian Federation
Russian Federation
Vladislav Yu. Golikov – Senior Researcher of the Medical Protection Laboratory
Mira Str., 8, Saint-Petersburg, 197101
L. A. Chipiga
Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being;
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies
Russian Federation
Russian Federation
Larisa A. Chipiga – Ph.D., research fellow;
research fellow
Saint-Petersburg
A. V. Vodovatov
Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being;
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Aleksandr V. Vodovatov – Ph.D., Head of Protection Laboratory, Leading Researcher;
docent
Saint-Petersburg
M. Ya. Smolyarchuk
Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Department of Health
Russian Federation
Russian Federation
Maksim Ya. Smolyarchuk – deputy chief specialist in nuclear medicine
Moscow
References
1. ICRP. Publication 103. The 2007 Recommendations of the International Commission on Radiological Protection. Ann. ICRP 37(2–4); 2007. 332 p.
2. ICRP. Publication 105. Radiological protection in medicine. Ann. ICRP 37(6); 2007. 63 p.
3. ICRP. Publication 94. Release of patients after therapy with unsealed radionuclides. Ann. ICRP 34(2); 2004. 80 p.
4. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35(10): 1941-1959.
5. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, KraeberBodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging. 2011;38(7): 1393-1406.
6. Marcel P, Stokkel M, Handkiewicz JD, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37: 2218–2228.
7. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2008; 35: 1039–1047.
8. Zaknun JJ, Bodei L, Mueller-Brand J, Baum RP, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2013;40(5): 800-816.
9. Narkevich BY, Lysak YV. Radiation Safety in the Ambulatory Use of Therapeutic Radiopharmaceuticals. Meditsinskaya radiologiya i radiatsionnaya bezopasnost = Medical radiology and radiation safety. 2015;60(4): 27-35. (In Russian).
10. Rushforth DP, Pratt BE, Chittenden SJ, Murray IS, Causer L, Grey MJ, et al. InfuShield: a shielded enclosure for administering therapeutic radioisotope treatments using standard syringe pumps. Nuclear Medicine Communications. 2017;38(3): 266–252.
11. IAEA. Radiation Protection in the Design of Radiotherapy Facilities. Safety Report Series No. 47. International Atomic Energy Agency, Vienna; 2006. 129 p.
12. Delacroix D, Guerre JP, Leblanc P, Hickman C. Radionuclide and radiation protection data handbook. Radiation Protection Dosimetry. 2002;98(1): 1–168.
13. Schleien B, Birky B, Slaback I. Handbook of health physics and radiological health. 3rd edn. Williams and Wilkins, Baltimore, MD. 1998. 700 p.
14. Mashkovich VP, Kudryavtseva AV. Protection from ionizing radiation. Reference Book. 4th edn. Moscow: Energoatomizdat; 1995. 496 p. (In Russian).
15. ICRP. Publication 107. Nuclear decay data for dosimetric calculations. Ann. ICRP 38(3); 2008. 96 p.
16. Data analysis software system StatSoft, Inc. STATISTICA, version 10. 2011. Available from: www.statsoft.com. [Accessed November 12, 2020].
17. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35: 1039–1047.
18. Al-Haj AN, Lagarde CS, Lobriguito AM. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment Health Physics. 2007;93(6): 656-666.
19. Willegaignon J, Malvestiti LF, Guimarães MIC, Sapienza MT, Endo IS, Neto GC, et al. 131I effective half-life for patients with thyroid cancer. Health Physics. 2006;91(2): 119-122.
Review
For citations:
Golikov V.Yu., Chipiga L.A., Vodovatov A.V., Smolyarchuk M.Ya. Some aspects of radiation protection in radionuclide therapy departments. Radiatsionnaya Gygiena = Radiation Hygiene. 2021;14(1):75-85. (In Russ.) https://doi.org/10.21514/1998-426X-2021-14-1-75-85
Views:
902
Email this article 